Information Provided By: 
Fly News Breaks for October 7, 2019
BTAI
Oct 7, 2019 | 07:39 EDT
Canaccord analyst Sumant Kulkarni said the weakness in BioXcel Therapeutics is a buying opportunity as he believes the current pullback is due to the current period of tepid sentiment for small/mid-cap biopharma with company having several catalysts over the next 12-18 months. The analyst reiterated his Buy rating and $24 price target on BioXcel Therapeutics shares.
News For BTAI From the Last 2 Days
BTAI
Apr 15, 2024 | 06:48 EDT
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on BioXcel Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm adjusted the company's model to account for last month's equity financing.
